GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $18.00 price objective on the stock.

GeoVax Labs Trading Down 12.6 %

NASDAQ GOVX opened at $1.11 on Friday. The stock has a market capitalization of $10.47 million, a price-to-earnings ratio of -0.20 and a beta of 3.06. The stock has a 50-day moving average of $1.67 and a 200 day moving average of $2.13. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million. Equities analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the fourth quarter worth about $29,000. Virtu Financial LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at about $97,000. Citadel Advisors LLC purchased a new position in GeoVax Labs in the 4th quarter worth approximately $104,000. Finally, Geode Capital Management LLC boosted its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.